Citations

Mayo Clinic

Showing 10 of 108572 citations.

Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee
Dunbar, Nancy M. , Raval, Jay S. , Johnson, Andrew D. , Abikoff, Cori, Adamski, Jill , Cooling, Laura , Kim, Haewon C., Morgan, Shanna, Schmidt, Amy E. , Sloan, Steven R. , Su, Leon , Szczepiorkowski, Zbigniew M. , West, F. Bernadette, Wong, Edward C.C. , Schneiderman, Jennifer , Grossman, Brenda J. , Marques, Marisa B. , Dunbar, Nancy M , Raval, Jay S

Journal of Clinical Apheresis | July 21, 2016 | Volume: 32 | Issue: 4 | Pages: 215-223

10.1002/jca.21486 | PMID 27442906 Get It

AbstractBackgroundAlthough many apheresis centers offer extracorporeal photopheresis (ECP), little is known about current treatment practices.MethodsAn electronic survey was distributed to assess ECP practice internationally.ResultsOf 251 responses, 137 met criteria for analysis. Most respondents were from North America (80%). Nurses perform ECP at most centers (84%) and the majority of centers treat adults only (52%). Most centers treat fewer than 50 patients/year (83%) and perform fewer than 300 procedures/year (70%). Closed system devices (XTS and/or Cellex) are used to perform ECP at most centers (96%). The most common indications for ECP are acute/chronic skin graft versus host disease (89%) and cutaneous T‐cell lymphoma (63%). The typical wait time for ECP treatment is less than 2 weeks (91%). Most centers do not routinely perform quality control assessment of the collected product (66%). There are device‐specific differences in treatment parameters. For example, XTS users more frequently have a minimum weight limit (P = 0.003) and use laboratory parameters to determine eligibility for treatment (P = 0.03). Regardless of device used, the majority of centers assess the clinical status of the patient before each procedure. Greater than 50% of respondents would defer treatment for hemodynamic instability due to active sepsis or heart failure, positive blood culture in the past 24 h or current fever.ConclusionThis survey based study describes current ECP practices. Further research to provide evidence for optimal standardization of patient qualifications, procedure parameters and product quality assessment is recommended.
Introduction to Disability and Health for Preclinical Medical Students: Didactic and Disability Panel Discussion
Rogers, Julie M.G. , Morris, Megan A. , Hook, C. Christopher , Havyer, Rachel D. , Rogers, Julie M.

MedEdPORTAL | July 21, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.10429 | PMID 31008209 Get It

Defining ultrahigh-risk AL amyloidosis with VWF
Leung, Nelson , Leung, Nelson

Blood | July 21, 2016 | Volume: 128 | Issue: 3 | Pages: 320-322

10.1182/blood-2016-05-717488 | PMID 27445410 Get It

Incidence of Pocket Infection Postcardiac Device Implantation Using Antibiotic versus Saline Solution for Pocket Irrigation
Lakshmanadoss, Umashankar, Nuanez, Bonita, Kutinsky, Ilana , Khalid, Rizwan, Haines, David E. , Wong, Wai Shun

Pacing and Clinical Electrophysiology | July 21, 2016 | Volume: 39 | Issue: 9 | Pages: 978-984

10.1111/pace.12920 | PMID 27440320 Get It

BackgroundPreprocedure systemic antibiotic prophylaxis reduces infections in patients undergoing cardiac implantable electronic devices (CIEDs) implantations. Whether pocket irrigation with antibiotic solution offers any advantage over saline solution in CIED implantation is unknown.MethodsRecords from 327 consecutive patients who underwent CIED implantation by three operators from February 2011 to January 2014 were reviewed. From February 2011 to January 2012, the antibiotic solution was used for pocket irrigation; from February 2012 to January 2014, saline solution was used. All patients received preprocedural IV antibiotics. Baseline demographics, comorbidities, lab data, and occurrence of any pocket infection postimplant were collected.ResultsThere were 118 and 209 patients in the antibiotic solution and saline solution group, respectively. A total of four (1.2%) patients had CIED infection: two in the antibiotic solution group and two in the saline solution group. Median time to infection from implant date was 81.5 ± 35 days. Two patients (50%) had infection after first device implantation. Of the four patients, one had positive blood culture, three had positive pocket cultures, one had lead vegetation, one underwent pocket exploration, and all of them had devices/leads extracted, with reimplantation on the contralateral side. No mortality was observed due to infectious complications.ConclusionWhen compared to pocket irrigation in the antibiotic solution group, the saline solution group was not associated with increased incidence of infectious complications after CIED implantation. The use of saline solution pocket irrigation alone may be used in CIED pocket irrigation periprocedurally. Further evaluation in larger randomized trials is needed.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Avet‐Loiseau, Hervé , Dimopoulos, Meletios Α. , Špıčka, Ivan , Masszi, Tamás , Hájek, Roman , Rosiñol, Laura , Mihaylov, Georgi , Maisnar, Vladimír , Mateos, María‐Victoria , Wang, Michael , Niesvizky, Rubén, Oriol, Albert , Minařík, Jiří , Palumbo, Antonio , Bensinger, William, Kukreti, Vishal , Ben‐Yehuda, Dina, Stewart, A. Keith, Obreja, Mihaela, Moreau, Philippe , Nahi, Hareth , Goranova‐Marinova, Veselina , Fonseca, Rafaël , Siegel, David S. , Goranova-Marinova, Vesselina S , Jakubowiak, Andrzej , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , Masszi, Tamas , Nahi, Hareth , Oriol, Albert

Blood | July 21, 2016 | Volume: 128 | Issue: 9 | Pages: 1174-1180

10.1182/blood-2016-03-707596 | PMID 27439911 Get It

Key Points KRd has a favorable benefit-risk profile compared with Rd, regardless of baseline cytogenetic risk status, in patients with relapsed MM. KRd improves but does not abrogate the poor prognosis associated with high-risk cytogenetics in patients with relapsed MM.
Fast men slow more than fast women in a 10 kilometer road race
Addona, Vittorio , Carter, Rickey E. , Joyner, Michael J. , Hunter, Sandra K. , Deaner, Robert O. , Hunter, Sandra K , Carter, Rickey E , Joyner, Michael J

PeerJ | July 21, 2016 | Volume: 4 | Issue: No issue available | Pages: e2235

10.7717/peerj.2235 | PMID 27547544 Get It

Background. Previous studies have demonstrated that men are more likely than women to slow in the marathon (footrace). This study investigated whether the sex difference in pacing occurs for a shorter race distance. Materials & Methods. Data were acquired from the Bolder Boulder 10 km road race for the years 2008–2013, which encompassed 191,693 performances. There were two pacing measures, percentage change in pace of the first 3 miles relative to the final 3.2 miles and percentage change in pace of the first mile relative to the final 5.2 miles. Pacing was analyzed as a continuous variable and as two categorical variables, as follows: “maintain the pace,” defined as slowing <5% and “marked slowing,” defined as slowing ≥10%. Results. Among the fastest ( men < 48:40; women < 55:27) and second fastest ( men < 53:54; women < 60:28) sex-specific finishing time sextiles, men slowed significantly more than women with both pacing measures, but there were no consistently significant sex differences in pacing among the slower four sextiles. For the fastest sextile, the odds for women were 1.96 (first pacing measure) and 1.36 (second measure) times greater than men to maintain the pace. For the fastest sextile, the odds for women were 0.46 (first measure) and 0.65 (second measure) times that of men to exhibit marked slowing. Multiple regression indicated that being older was associated with lesser slowing, but the sex difference among faster runners persisted when age was controlled. Conclusions. There was a sex difference in pacing during a 10 km race where glycogen depletion is not typically relevant. These results support the hypothesis that the sex difference in pacing partly reflects a sex difference in decision making.
Point-Counterpoint: A Nucleic Acid Amplification Test for Streptococcus pyogenes Should Replace Antigen Detection and Culture for Detection of Bacterial Pharyngitis
Pritt, Bobbi S. , Patel, Robin , Kirn, Thomas J., Thomson, Richard B., Patel, Robin , Pritt, Bobbi S

Journal of Clinical Microbiology | July 21, 2016 | Volume: 54 | Issue: 10 | Pages: 2413-2419

10.1128/jcm.01472-16 | PMID 27440817 Get It

ABSTRACT Nucleic acid amplification tests (NAATs) have frequently been the standard diagnostic approach when specific infectious agents are sought in a clinic specimen. They can be applied for specific agents such as S. pyogenes , or commercial multiplex NAATs for detection of a variety of pathogens in gastrointestinal, bloodstream, and respiratory infections may be used. NAATs are both rapid and sensitive. For many years, S. pyogenes testing algorithms used a rapid and specific group A streptococcal antigen test to screen throat specimens, followed, in some clinical settings, by a throat culture for S. pyogenes to increase the sensitivity of its detection. Now S. pyogenes NAATs are being used with increasing frequency. Given their accuracy, rapidity, and ease of use, should they replace antigen detection and culture for the detection of bacterial pharyngitis? Bobbi Pritt and Robin Patel of the Mayo Clinic, where S. pyogenes NAATs have been used for well over a decade with great success, will explain the advantages of this approach, while Richard (Tom) Thomson and Tom Kirn of the NorthShore University HealthSystem will discuss their concerns about this approach to diagnosing bacterial pharyngitis.
Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
Quick, Laura , Henrich, Ian C. , Asmann, Yan W. , Oliveira, André M. , Chou, Margaret M. , Wang, Xiaoke, Young, Robert , Wang, Xiaoke

Cancer Research | July 20, 2016 | Volume: 76 | Issue: 18 | Pages: 5337-5347

10.1158/0008-5472.can-15-2391 | PMID 27440725 Get It

Abstract Bone and soft tissue tumors (BSTT) are relatively poorly understood, hampering the development of effective therapies. Here we report a critical effector pathway for the ubiquitin-specific protease 6 (USP6)/TRE17 oncogene, which is overexpressed upon chromosome translocation in various human tumors, including aneurysmal bone cyst (ABC) and the related benign lesion nodular fasciitis. Ectopic expression of USP6 is known to drive formation of tumors, which recapitulate key features of ABC and nodular fasciitis; however, the identity of USP6′s relevant substrates has been obscure. Here we report that the Jak1–STAT3 signaling pathway serves as an essential effector of USP6 in BSTT formation. We found that USP6 directly deubiquitinated Jak1, leading to its stabilization and activation of STAT3. The tumorigenic potential of USP6 was attenuated significantly by CRISPR-mediated deletion of Jak1 or STAT3, or by administration of a Jak family inhibitor. Analysis of primary clinical samples of nodular fasciitis confirmed the activation of a Jak1–STAT3 gene signature in vivo. Together, our studies highlight Jak1 as the first identified substrate for USP6, and they offer a mechanistic rationale for the clinical investigation of Jak and STAT3 inhibitors as therapeutics for the treatment of bone and soft tissue tumors along with other neoplasms driven by USP6 overexpression. Cancer Res; 76(18); 5337–47. ©2016 AACR.
Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis
Bergquist, John R. , Storlie, Curtis B. , Groeschl, Ryan T., Tee, May C. , Habermann, Elizabeth B. , Smoot, Rory L. , Kendrick, Michael L. , Farnell, Michael B., Roberts, Lewis R. , Nagorney, David M. , Truty, Mark J. , Ivanics, Tommy , Gores, Gregory J. , Roberts, Lewis R , Smoot, Rory L , Habermann, Elizabeth , Bergquist, John R

Journal of Surgical Oncology | July 20, 2016 | Volume: 114 | Issue: 4 | Pages: 475-482

10.1002/jso.24381 | PMID 27439662 Get It

Astrocyte signaling and synaptic homeostasis
Benarroch, Eduardo E.

Neurology | July 20, 2016 | Volume: 87 | Issue: 7 | Pages: 726-735

10.1212/wnl.0000000000003019 | PMID 27440147 Get It